Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.170 -0.240 (-2.85%)

Streaming Delayed Price Updated: 9:54 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ↗

November 18, 2024

Via Benzinga

5 Analysts Have This To Say About Regenxbio ↗

November 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 06, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Regenxbio ↗

October 10, 2024

Via Benzinga

Assessing Regenxbio: Insights From 5 Financial Analysts ↗

September 04, 2024

Via Benzinga

Where Regenxbio Stands With Analysts ↗

August 05, 2024

Via Benzinga

Assessing Regenxbio: Insights From 4 Financial Analysts ↗

June 07, 2024

Via Benzinga

Evaluating Regenxbio: Insights From 9 Financial Analysts ↗

May 15, 2024

Via Benzinga

Where Regenxbio Stands With Analysts ↗

April 12, 2024

Via Benzinga

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

Why Is Clearside Biomedical Stock Gaining Today? ↗

June 25, 2024

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS...

Via Benzinga

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock ↗

March 06, 2024

Via Benzinga

Regenxbio: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗

June 20, 2024

The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.

Via Investor's Business Daily

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

A Preview Of Regenxbio's Earnings ↗

February 26, 2024

Via Benzinga

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 25, 2024

Via Benzinga

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗

March 13, 2024

The threat is still emerging, but it could be significant.

Via The Motley Fool

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗

March 08, 2024

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.

Via Benzinga

REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars ↗

March 05, 2024

Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 05, 2024

Via Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 01, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

REGENXBIO Inc. - Common Stock (NQ:RGNX)

All News about REGENXBIO Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today